Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Twitter Feed
-
It is UCB’s goal to develop and produce medicines for people with severe diseases in the most environmentally sustainable way possible. Interested in learning how we do this? ✅Check out our UCB Integrated Annual Report 2018. https://t.co/HdntLyAAbQ ht
— UCB News (@ucb_news) 16.04.2019 -
Patients can help make medicines development more efficient and user-friendly. We are pleased to support @imi_paradigm in accelerating uptake of #PatientEngagement https://t.co/s8vpvGhaKd https://t.co/vrFFplHGID
— UCB News (@ucb_news) 16.04.2019 -
What has the new mathematical field of ‘network science’ got to do with bringing innovative medicines to patients who need them? Find out the answer from Bram at https://t.co/nTUueuplnF https://t.co/tiQAjR4Nut
— UCB News (@ucb_news) 15.04.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
